BURLINGAME, Calif.--(BUSINESS WIRE)--Humanigen, Inc., (HGEN) (Humanigen), a clinical stage biopharmaceutical company focused on preventing and treating cytokine storm with lenzilumab, the companys proprietary Humaneered anti-human granulocyte macrophage-colony stimulating factor (GM-CSF) monoclonal antibody, announced data on the first clinical use of lenzilumab in 12 COVID-19 patients. The manuscript, titled First Clinical Use of Lenzilumab to Neutralize GM-CSF in Patients with Severe and Critical COVID-19 Pneumonia was published online at medRxiv.org (www.medrxiv.org/content/10.1101/2020.06.08.20125369v1). Patients showed rapid clinical improvement with a median time to recovery of five days, median time to discharge of five days and 100% survival to the data cut-off date. Patients also demonstrated rapid improvement in oxygenation, temperature, inflammatory cytokines and key hematological parameters consistent with improved clinical outcomes.
Dr. Zelalem Temesgen, Professor of Medicine at Mayo Clinic and one of the key authors of the study, said, Lenzilumab use was associated with improved clinical outcomes and oxygen requirement, with no reported mortality. We did not observe any treatment-emergent adverse events attributable to lenzilumab and it was well-tolerated. Based on the pathophysiology of cytokine storm following SARS-CoV-2 infection, along with work conducted at Mayo Clinic on GM-CSF depletion in CAR-T therapy, lenzilumab may offer a rational approach to ameliorate the consequences of cytokine storm in COVID-19.
Dr. Cameron Durrant, chief executive officer of Humanigen, stated, It is extremely encouraging to see this initial group of high-risk patients with severe and critical COVID-19 pneumonia show clinical improvement on lenzilumab, and at the data cut-off point, 11 of them discharged from the hospital. All 12 patients had at least one risk factor associated with poor outcomes, such as age, smoking history, cardiovascular disease, diabetes, chronic kidney disease, chronic lung disease, high BMI, and elevated inflammatory markers, with several patients having multiple such risk factors.
All patients were hospitalized in the Mayo Clinic system and had severe or critical pneumonia as a result of COVID-19. They were also viewed as being at high risk of further disease progression. All patients required oxygen supplementation and had elevation in at least one inflammatory biomarker prior to receiving lenzilumab. All patients had at least one co-morbidity associated with poor outcomes in COVID-19 and several patients had multiple co-morbidities: 58% had diabetes mellitus, 58% had hypertension, 58% had underlying lung diseases, 50% were obese (defined as a BMI greater than 30), 17% had chronic kidney disease and 17% had coronary artery disease. The median age was 65 years.
More details on the companys programs in COVID-19 can be found on the companys website at http://www.humanigen.com under the COVID-19 tab, and details of the Phase III potential registration study can be found at clinicaltrials.gov using ClinicalTrials.gov Identifier NCT04351152.
About COVID-19
COVID-19 is an infectious disease caused by SARS-CoV-2. COVID-19 has become a global pandemic, with almost 8 million confirmed cases and almost 450,000 deaths reported to date. Patients with severe cases of COVID-19 experience severe viral pneumonia that can progress to acute respiratory distress syndrome (ARDS), respiratory failure and death.
In severe and critical patients with COVID-19, published research suggests GM-CSF as the key link between pathogenic Th1 cells and inflammatory monocytes, which secrete additional GM-CSF1. Lenzilumab is a late clinical-stage, monoclonal antibody targeting GM-CSF, a pro-inflammatory cytokine up-regulated in the serum of COVID-19 patients2. The percentages of certain GM-CSF-expressing cells are significantly higher in the blood of ICU-admitted COVID-19 patients compared with healthy controls and are more pronounced in ICU-admitted COVID-19 patients versus non-ICU patients2.
1. Zhou Y, Fu B, Zheng X, et al. Aberrant pathogenic GM-CSF+ T cells and inflammatory CD14+CD16+ monocytes in severe pulmonary syndrome patients of a new coronavirus. Pre-Print. 2020. https://doi.org/10.1101/2020.02.12.945576.
2. Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/s0140-6736(20)30183-5.
About Humanigen, Inc.
Humanigen, Inc. is developing its portfolio of clinical and pre-clinical therapies for the treatment of inflammation and cancers via its novel, cutting-edge GM-CSF neutralization and gene-knockout platforms. We believe that our GM-CSF neutralization and gene-editing platform technologies have the potential to reduce the inflammatory cascade associated with coronavirus infection as well as the serious and potentially life-threatening CAR-T therapy-related side effects while preserving and potentially improving the efficacy of the CAR-T therapy itself, thereby breaking the efficacy/toxicity linkage. The companys immediate focus is to prevent or minimize the cytokine storm that precedes severe lung dysfunction and ARDS in serious cases of SARS-CoV-2 infection and also in combining FDA-approved and development stage CAR-T therapies with lenzilumab, the companys proprietary Humaneered anti-human-GM-CSF immunotherapy, which is its lead product candidate. A potential registrational Phase III study in COVID-19 patients is currently enrolling. The company is also exploring the effectiveness of its GM-CSF neutralization technologies (either through the use of lenzilumab as a neutralizing antibody or through GM-CSF gene knockout) in combination with other CAR-T, bispecific or natural killer (NK) T- cell engaging immunotherapy treatments to break the efficacy/toxicity linkage, including to prevent and/or treat graft-versus-host disease (GvHD) in patients undergoing allogeneic hematopoietic stem cell transplantation (HSCT). For more information, visit http://www.humanigen.com
Forward-Looking Statements
This release contains forward-looking statements. Forward-looking statements reflect management's current knowledge, assumptions, judgment and expectations regarding future performance or events. Although management believes that the expectations reflected in such statements are reasonable, they give no assurance that such expectations will prove to be correct and you should be aware that actual events or results may differ materially from those contained in the forward-looking statements. Words such as "will," "expect," "intend," "plan," "potential," "possible," "goals," "accelerate," "continue," and similar expressions identify forward-looking statements, including, without limitation, statements regarding our expectations for the Phase III study and the potential future development of lenzilumab to minimize or reduce the severity of lung dysfunction associated with severe and critical COVID-19 infections or to be approved by FDA for such use or to help CAR-T reach its full potential or to deliver benefit in preventing GvHD. Forward-looking statements are subject to a number of risks and uncertainties including, but not limited to, the risks inherent in our lack of profitability and potential need for additional capital to conduct the Phase III study and grow our business; our dependence on partners to further the development of our product candidates; the uncertainties inherent in the development and launch of any new pharmaceutical product; the outcome of pending or future litigation; and the various risks and uncertainties described in the "Risk Factors" sections and elsewhere in the Company's periodic and other filings with the Securities and Exchange Commission.
All forward-looking statements are expressly qualified in their entirety by this cautionary notice. You should not place undue reliance on any forward-looking statements, which speak only as of the date of this release. We undertake no obligation to revise or update any forward-looking statements made in this press release to reflect events or circumstances after the date hereof or to reflect new information or the occurrence of unanticipated events, except as required by law.
Read the rest here:
Mayo Clinic Study of Humanigen's Lenzilumab Shows Rapid Recovery and Discharge in Severe and Critical COVID-19 Patients - Business Wire
- Day +22 [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Milk Teeth Stem Cell Banking [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Multiple Sclerosis Adult Stem Cell Therapy [Last Updated On: August 4th, 2011] [Originally Added On: August 4th, 2011]
- Stem Cell Therapy for Autism: A Proposal [Last Updated On: August 5th, 2011] [Originally Added On: August 5th, 2011]
- Dr Omar Gonzalez [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- American Stem Cell Clinic Corporate Video [Last Updated On: August 7th, 2011] [Originally Added On: August 7th, 2011]
- Multiple Sclerosis Stem Cell Therapy News Coverage [Last Updated On: August 9th, 2011] [Originally Added On: August 9th, 2011]
- Dr Brothers, OD Part 2 Following Stem Cell Patients [Last Updated On: August 13th, 2011] [Originally Added On: August 13th, 2011]
- Dr Brothers, OD Part 1 Following Stem Cell Patients [Last Updated On: August 15th, 2011] [Originally Added On: August 15th, 2011]
- Panama City Beach FL: First In-Clinic Adipose Stem Cell Procedure [Last Updated On: August 16th, 2011] [Originally Added On: August 16th, 2011]
- Stem Cell Therapy for Type II Diabetes [Last Updated On: August 17th, 2011] [Originally Added On: August 17th, 2011]
- Dr. Andre Terzic - Smart Stem Cells [Last Updated On: September 5th, 2011] [Originally Added On: September 5th, 2011]
- Autologous Blood and Marrow Transplant at Mayo Clinic 3 [Last Updated On: September 6th, 2011] [Originally Added On: September 6th, 2011]
- Human Embryonic Stem Cell Therapy: Pathway to the Clinic [Last Updated On: September 8th, 2011] [Originally Added On: September 8th, 2011]
- Mayo Clinic Study Shows Induced Pluripotent Stem Cells Repair Heart [Last Updated On: September 9th, 2011] [Originally Added On: September 9th, 2011]
- Kansas' First In-Clinic Adipose Stem Cell Procedure [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Breast Augmentation with Autologous Stem Cells at Clinic DDr. Heinrich® [Last Updated On: September 11th, 2011] [Originally Added On: September 11th, 2011]
- Anna Deeter Testimonial for Fetal Stem Cell Treatment at EmCell Clinic [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- MediVet Canada performs the first In-Clinic Stem Cell Procedure [Last Updated On: September 20th, 2011] [Originally Added On: September 20th, 2011]
- Embryonic Stem Cells From Skin: Making Old Cells Young [Last Updated On: September 22nd, 2011] [Originally Added On: September 22nd, 2011]
- The Politics of Stem Cell Research [Last Updated On: September 25th, 2011] [Originally Added On: September 25th, 2011]
- STEM CELL FOR KIDNEY FAILURE - MUMBAI.wmv [Last Updated On: September 26th, 2011] [Originally Added On: September 26th, 2011]
- Adult Stem Cells and Cancer [Last Updated On: September 28th, 2011] [Originally Added On: September 28th, 2011]
- ACT - Stem Cell Trial for AMD and Stargardt - Phase 1 [Last Updated On: September 29th, 2011] [Originally Added On: September 29th, 2011]
- Stem Cell Health Alliance - Breakthrough to Independence [Last Updated On: September 30th, 2011] [Originally Added On: September 30th, 2011]
- Professor waarschuwt tegen commerciële stamcelklinieken [Last Updated On: October 3rd, 2011] [Originally Added On: October 3rd, 2011]
- Austin clinic to bank adult stem cells [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Dr. Gonzalez and his Integrative Medicine clinic in Mexico [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Cell Therapy Clinic EmCell [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- STEM CELL THERAPY FOR PARALYSIS, MUMBAI.wmv [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Clinic Embryos and Stem Cell Research [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- Affordable Stem Cell Therapy in Guatemala (2hrs from Miami) [Last Updated On: October 4th, 2011] [Originally Added On: October 4th, 2011]
- "Molly" - Before and After Stem Cell Therapy [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Mayo Clinic Regenerative Medicine Consult Service [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Houston veterinarian uses cutting-edge stem cell technology on dogs [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Ruby, Olsen Veterinary Clinic: Day 1 Stem Cell Procedure [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- A Dose of Reality on Alternative Stem Cell Treatments: What you don't know can hurt you [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- The Next Frontier in Stem Cell Research [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- stem cell trial for leading causes of blindness [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Better in Beijing. video 3 [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Ruby, Olsen Veterinary Clinic 30 Days after Stem Cell Treatment [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- Mesenchymal Stem Cells Drive New MS Study/Treatment [Last Updated On: October 6th, 2011] [Originally Added On: October 6th, 2011]
- New stem cell procedure in BC for Ellie at the Kamloops Veterinary Clinic-April 26 [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Stem Cell Face Lift [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Bringing Stem Cell Cures to the Clinic: UC Davis GMP Facility [Last Updated On: October 7th, 2011] [Originally Added On: October 7th, 2011]
- Michigan Law on Stem Cells [Last Updated On: October 8th, 2011] [Originally Added On: October 8th, 2011]
- Stem Cell Therapy for Multiple Sclerosis (MS patient) - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Fat Stem Cell Therapy Publication - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Public Symposium: The Stem Cell Promise: Moving to the Clinic - Video [Last Updated On: October 14th, 2011] [Originally Added On: October 14th, 2011]
- Becoming a Blood Stem Cell Donor - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Stem cell vet treatment performed in Ontario - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- STEM CELLS TRANSPLANTATION - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Home Town Company has brought Stem Cell - Video [Last Updated On: October 21st, 2011] [Originally Added On: October 21st, 2011]
- Bone Marrow Stem Cells - Video [Last Updated On: October 22nd, 2011] [Originally Added On: October 22nd, 2011]
- Endogenous Stem Cell Therapy for Diabetes - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Immune Control of Stem Cell Mobilization - Video [Last Updated On: October 25th, 2011] [Originally Added On: October 25th, 2011]
- Utah's First In-Clinic Stem Cell Procedure - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Medical tourism in Croatia - Smart Stem Cells by Dr. Andre Terzic, Mayo Clinic - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- reconstrutive nose surgery(nose job to revise),stem cell - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Baby Elsa Blood and Bone Marrow Match Clinic - Video [Last Updated On: November 12th, 2011] [Originally Added On: November 12th, 2011]
- Panama City Beach, FL: First In-Clinic Adipose Stem Cell Procedure - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- India Trip - Video [Last Updated On: November 13th, 2011] [Originally Added On: November 13th, 2011]
- Man Cured of Arthritis Using Stem Cells at Clinic in Panama - Video [Last Updated On: November 30th, 2011] [Originally Added On: November 30th, 2011]
- Fat Stem Cell Therapy for Multiple Sclerosis - Video [Last Updated On: December 2nd, 2011] [Originally Added On: December 2nd, 2011]
- Amanda and Britney BCC Table Clinic 2011 - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Using Your Own Fat Stem Cells For Arthritis, Sports Injuries and Autoimmune Disorders - Video [Last Updated On: December 13th, 2011] [Originally Added On: December 13th, 2011]
- Adult Stem Cell therapy for COPD -Real patient results, USA Stem Cells- Donald W. Testimonial - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Lgr5 Stem Cells and Cancer - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Dogs Recieve Stem Cell Treatment - Video [Last Updated On: January 5th, 2012] [Originally Added On: January 5th, 2012]
- Dr. Steenblock's Office- STEM CELL Clinic - Video [Last Updated On: January 21st, 2012] [Originally Added On: January 21st, 2012]
- Reuben Before and after Stem Cell Therapy - Video [Last Updated On: January 23rd, 2012] [Originally Added On: January 23rd, 2012]
- My India Trip#1 Photos - Video [Last Updated On: January 23rd, 2012] [Originally Added On: January 23rd, 2012]
- Stem Cell Financing - Video [Last Updated On: January 25th, 2012] [Originally Added On: January 25th, 2012]
- Stem Cell's in Sarasota by Regenerative clinic for Meniscus Damage. - Video [Last Updated On: January 30th, 2012] [Originally Added On: January 30th, 2012]
- StemCells, Inc. Announces Publication of Preclinical Data Demonstrating Its Human Neural Stem Cells Preserve Vision [Last Updated On: January 30th, 2012] [Originally Added On: January 30th, 2012]
- Stoney Creek firm licenses stem cell technology [Last Updated On: February 3rd, 2012] [Originally Added On: February 3rd, 2012]
- Bonita stem cell doctor's attorney quits, state hearing still scheduled [Last Updated On: February 5th, 2012] [Originally Added On: February 5th, 2012]
- From the Avro disappointment to the gift of stem-cell research [Last Updated On: February 6th, 2012] [Originally Added On: February 6th, 2012]
- $30 million donation from Boris family will help McMaster turn stem cell research into therapy [Last Updated On: February 6th, 2012] [Originally Added On: February 6th, 2012]
- Researchers make breakthrough in stem cell research [Last Updated On: February 13th, 2012] [Originally Added On: February 13th, 2012]